Monoclonal B-cell lymphocytosis; not the same as B-cell chronic lymphocytic leukaemia.

CONCLUSIONS: The findings of this study indicate that a sizeable fraction of MBL patients are diagnosed inaccurately with CLL, even after the introduction of the MBL diagnosis. FUNDING: The Danish Cancer Society. TRIAL REGISTRATION: not relevant. PMID: 29206098 [PubMed - in process]
Source: Danish Medical Journal - Category: General Medicine Tags: Dan Med J Source Type: research

Related Links:

In this study, we describe two novel ATM rearrangements in 2 patients with CLL and T-PLL.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Source Type: research
Publication date: Available online 18 June 2018Source: The Lancet HaematologyAuthor(s): Gita Thanarajasingam, Lori M Minasian, Frederic Baron, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F Little, Francois-Xavier MahonSummaryTremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have inc...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Publication date: Available online 18 June 2018Source: Seminars in Cancer BiologyAuthor(s): Djordje Atanackovic, Tim LuetkensAbstractIn the past few years we have seen remarkable paradigm shifts in the treatment of many solid tumors due to the introduction of inhibitors targeting immune checkpoints such as PD-1/PD-L1 and CTLA-4. Recent results indicate that checkpoint inhibition also represents a very promising approach for certain types of hematologic malignancies. Unfortunately, treatment with checkpoint inhibitors is also associated with substantial toxicities and high costs and only a subset of patients appears to deri...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
This study aimed to answer both questions.Patients and MethodsWe reviewed 14 Alliance for Clinical Trials in Oncology trials that enrolled CLL and/or NHL patients between 2004–2014. Toxicity was assessed per the NCI-CTCAE (version 3–5). Probabilities of experiencing grade three or four hematologic and non-hematologic toxicities were modeled as a function of clinical and disease-related factors using logistic regression.Results1199 patients (409 age ≥ 65; 790 age 
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 5 April 2018Source: Acta Pharmaceutica Sinica BAuthor(s): Zijun Zhao, Yu Chen, Ngiambudulu M. Francisco, Yuanqing Zhang, Minhao WuAbstractChimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. The whole procedure of CAR-T cell production is not well understood. The CAR-T cell has been used predominantly in t...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) is the most prevalent lymphoid malignancy in the United States, with approximately 140,000 people living with the disease [1]. Immune dysfunction is an early and clinically important complication of CLL [2]. Patients with CLL are at significantly increased risk of skin cancer including melanoma, and have a ~2-fold increased risk of mortality from these second malignancies compared to patients without a preceding diagnosis of CLL [3 –7].
Source: Leukemia Research - Category: Hematology Authors: Tags: Research paper Source Type: research
Publication date: Available online 18 June 2018Source: The Lancet HaematologyAuthor(s): Gita Thanarajasingam, Lori M Minasian, Frederic Baron, Franco Cavalli, R Angelo De Claro, Amylou C Dueck, Tarec C El-Galaly, Neil Everest, Jan Geissler, Christian Gisselbrecht, John Gribben, Mary Horowitz, S Percy Ivy, Caron A Jacobson, Armand Keating, Paul G Kluetz, Aviva Krauss, Yok Lam Kwong, Richard F Little, Francois-Xavier MahonSummaryTremendous progress in treatment and outcomes has been achieved across the whole range of haematological malignancies in the past two decades. Although cure rates for aggressive malignancies have inc...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Publication date: Available online 18 June 2018Source: Seminars in Cancer BiologyAuthor(s): Djordje Atanackovic, Tim LuetkensAbstractIn the past few years we have seen remarkable paradigm shifts in the treatment of many solid tumors due to the introduction of inhibitors targeting immune checkpoints such as PD-1/PD-L1 and CTLA-4. Recent results indicate that checkpoint inhibition also represents a very promising approach for certain types of hematologic malignancies. Unfortunately, treatment with checkpoint inhibitors is also associated with substantial toxicities and high costs and only a subset of patients appears to deri...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
This study aimed to answer both questions.Patients and MethodsWe reviewed 14 Alliance for Clinical Trials in Oncology trials that enrolled CLL and/or NHL patients between 2004–2014. Toxicity was assessed per the NCI-CTCAE (version 3–5). Probabilities of experiencing grade three or four hematologic and non-hematologic toxicities were modeled as a function of clinical and disease-related factors using logistic regression.Results1199 patients (409 age ≥ 65; 790 age 
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 5 April 2018Source: Acta Pharmaceutica Sinica BAuthor(s): Zijun Zhao, Yu Chen, Ngiambudulu M. Francisco, Yuanqing Zhang, Minhao WuAbstractChimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. The whole procedure of CAR-T cell production is not well understood. The CAR-T cell has been used predominantly in t...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Denmark Health | General Medicine | Leukemia | Lymphoma | Study